UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023286
Receipt number R000026830
Scientific Title Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease
Date of disclosure of the study information 2016/07/23
Last modified on 2021/06/23 06:24:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease

Acronym

Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease

Scientific Title

Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease

Scientific Title:Acronym

Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease

Region

Japan


Condition

Condition

nonalcoholic fatty liver disease

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate which markers more accurately reflect the fibrosis stage in patients with nonalcoholic fatty liver disease

Basic objectives2

Others

Basic objectives -Others

To evalute the values of sensitivity and specificity for various biomarkers in each fibrosis stage.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The values of AUC, sensitivity, specificity, PPV, and NPV for various biomarkers.
Correlation between serum fibrotic markers for predicting liver fibrosis.

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

1,Taking alcohol less than 20g/day for female and 30g/day for male respectively
2,patients diagnosed as NAFLD by liver biopsy

Key exclusion criteria

1,alcohol abuse (quantity of ethanol intake more than 20g/day for female and 30g/day for male respectively)
2,type 1 diabetes,
3,positive HBs antigen, HCV antibody, or HIV antibody,
4,other liver diseases, such as autoimmune hepatitis, primary biliary cirrhosis, and drug-induced liver disorder
5,being treated with oral vitamin E preparation and thiazolidinediones for NAFLD or other disorders

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Masanori
Middle name
Last name Masanori Atsukawa

Organization

Nippon Medical School Chiba Hokusoh Hospital

Division name

Division of Gastroenterology

Zip code

270-1196

Address

1715,Kamakari,Inzai,Chiba, 270-1694, Japan

TEL

0476-99-1111

Email

atsukawa-nms@umin.ac.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Atsukawa

Organization

Nippon Medical School Chiba Hokusoh Hospital

Division name

Division of Gastroenterology

Zip code

2701613

Address

1715,Kamakari,Inzai,Chiba, 270-1694, Japan

TEL

0476-99-1111

Homepage URL


Email

atsukawa-nms@umin.ac.jp


Sponsor or person

Institute

Nippon Medical School Chiba Hokusoh Hospital

Institute

Department

Personal name



Funding Source

Organization

Nippon Medical School Chiba Hokusoh Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

National Center for Global Health and Medicine (NCGM)
Shinmatsudo Central General Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nippon Medical School Chiba Hokousoh Hospital

Address

1715 Kamagari Inzai Chiba

Tel

+81476991111

Email

araraki@nms.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本医科大学千葉北総病院(千葉県)Nippon Medical School Chiba Hokusoh Hospital
国立国際医療研究センター(千葉県)National Center for Global Health and Medicine (NCGM)
新松戸中央総合病院(千葉県)Shinmatsudo Central General Hospital (Chiba)


Other administrative information

Date of disclosure of the study information

2016 Year 07 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2016 Year 06 Month 17 Day

Date of IRB


Anticipated trial start date

2016 Year 06 Month 17 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Comparison of liver fibrosis biomarkers in patients with NAFLD diagnosed by liver biopsy


Management information

Registered date

2016 Year 07 Month 22 Day

Last modified on

2021 Year 06 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026830


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name